Dendritic Cell Cancer Vaccine Market Report 2026

The dendritic cell cancer vaccine market size has grown rapidly in recent years. It will grow from $2.71 billion in 2025 to $2.98 billion in 2026 at a compound annual growth rate (CAGR) of 10.1%. The growth in the historic period can be attributed to limitations of conventional cancer therapies, early success of sipuleucel-t, unmet needs in metastatic cancers, growth of immuno-oncology research, hospital-based vaccine administration.

The dendritic cell cancer vaccine market size is expected to see strong growth in the next few years. It will grow to $4.2 billion in 2030 at a compound annual growth rate (CAGR) of 8.9%. The growth in the forecast period can be attributed to advancements in cell therapy manufacturing, expansion of precision oncology, increasing regulatory support, rising cancer incidence, growing investment in immunotherapy pipelines. Major trends in the forecast period include growth of personalized cancer vaccines, expansion of clinical trials in solid tumors, increased focus on immune system modulation, rising adoption of combination immunotherapies, advancements in cell processing technologies.

The increasing incidence of cancer is anticipated to drive the growth of the dendritic cell cancer vaccine market in the coming years. Cancer is a disease marked by the uncontrolled growth and spread of abnormal cells within the body, often resulting in tumor formation and interference with normal bodily functions. The rise in cancer cases is influenced by factors such as lifestyle habits, environmental exposure, and genetic susceptibility. Dendritic cell cancer vaccines are used in cancer therapy to activate the body’s immune system to recognize and target cancer cells, potentially leading to improved patient outcomes. For example, in February 2024, according to the World Health Organization, a US-based intergovernmental organization, approximately 35 million new cancer cases are projected by 2050, representing a 77% increase compared to the estimated 20 million cases recorded in 2022. As a result, the growing number of cancer cases is contributing to the expansion of the dendritic cell cancer vaccine market.

Leading companies in the dendritic cell cancer vaccine market are concentrating on establishing strategic collaborations to develop cancer curative vaccines and improve clinical care for patients. Strategic collaborations involve formal partnerships between organizations designed to achieve shared and mutually beneficial objectives. For instance, in May 2023, the Walter and Eliza Hall Institute of Medical Research, an Australia-based medical research organization, partnered with the Peter MacCallum Cancer Centre, an Australia-based oncology research institute. This collaboration secured more than $900,000 in MRFF funding to develop a cancer vaccine for patients with limited treatment options. The initiative focuses on advancing dendritic cell-based vaccination approaches, which aim to enhance the patient’s immune cells to better combat cancer. The research builds on a significant discovery made at WEHI three decades ago and may lead to the first clinical trial involving cancer patients.

In November 2023, AbbVie Inc., a US-based biotechnology company, completed the acquisition of ImmunoGen, Inc. for an undisclosed sum. Through this acquisition, AbbVie seeks to broaden its portfolio of innovative therapies and reinforce its presence in the oncology market. ImmunoGen, Inc. is a US-based biotechnology firm specializing in the development and manufacture of antibody-drug conjugates (ADCs) for cancer treatment.

Major companies operating in the dendritic cell cancer vaccine market are Dendreon Pharmaceuticals LLC, Cognate BioServices Inc., Batavia Biosciences, Medigene AG, Zelluna Immunotherapy AS, Northwest Biotherapeutics, PDC*line Pharma SA, ImmunityBio Inc., Celldex Therapeutics Inc., Argos Therapeutics Inc., DCPrime, NuGenerex Immuno‑Oncology, ImmunoCellular Therapeutics Ltd., Immunicum AB, 3M Company, Activartis Biotech GmbH, DanDrit Biotech, Kiromic BioPharma Inc., GlaxoSmithKline plc, SOTIO, Vaxil BioTherapeutics.

North America was the largest region in the dendritic cell cancer vaccine market in 2025. The regions covered in the dendritic cell cancer vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the dendritic cell cancer vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the dendritic cell cancer vaccine market by increasing costs of imported cell processing equipment, biologic reagents, and cold-chain logistics components. Hospitals and cancer centers in North America and Europe are most affected due to reliance on imported cell therapy inputs, while Asia-Pacific faces higher infrastructure costs. These tariffs are increasing treatment development expenses. However, they are also encouraging domestic cell therapy manufacturing and localized vaccine production capabilities.

The dendritic cell cancer vaccine market research report is one of a series of new reports that provides dendritic cell cancer vaccine market statistics, including dendritic cell cancer vaccine industry global market size, regional shares, competitors with a dendritic cell cancer vaccine market share, detailed dendritic cell cancer vaccine market segments, market trends and opportunities, and any further data you may need to thrive in the dendritic cell cancer vaccine industry. This dendritic cell cancer vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Dendritic cell cancer vaccines are a form of immunotherapy that use the body’s dendritic cells to trigger an immune response against cancer cells, thereby improving the body’s ability to identify and eliminate tumors. These vaccines are applied as a personalized treatment strategy aimed at specific cancer types and strengthening the immune system’s capacity to fight the disease. By leveraging the body’s immune mechanisms, dendritic cell cancer vaccines may result in more effective and long-lasting therapeutic responses in patients.

The primary products in the dendritic cell cancer vaccine market include CreaVax, Sipuleucel-T (Provenge), and others. CreaVax is a dendritic cell cancer vaccine developed to stimulate the immune system against cancer cells by using specialized immune cells loaded with tumor-specific antigens. Distribution channels for these vaccines include hospitals, cancer centers, ambulatory surgical centers, and clinics. Their applications cover both pediatric and adult patients. Key end users include oncology centers, research institutions, and biopharmaceutical companies.

The dendritic cell cancer vaccines market consists of sales of autologous dendritic cell vaccines, allogeneic dendritic cell vaccines, and experimental vaccines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.